Lumos Pharma, Inc.
Lumos Pharma, Inc. (LUMO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · LUMO · as of Jun 9, 2026
Key Statistics
Explore Lumos Pharma, Inc. Data
lumo stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 7 · Buy rate: 57.1%
The LUMO analyst consensus is Buy, based on ratings from 7 Wall Street analysts over the past 3 months. The average 12-month price target is $16.50, representing +280.18% upside from the current price of $4.34.
Competitors & Peers
lumo competitorsLUMO
CERC
EYEN
GRCE
IRD
LIANYStock Performance
Full HistoryAbout Lumos Pharma, Inc.
Lumos Pharma, Inc. is a biopharmaceutical company in the clinical development stage, dedicated to advancing and commercializing medical treatments for rare conditions. Their principal therapeutic comp…
what is lumos pharma, inc. · lumo stock overview · lumos pharma, inc. company profile · who is lumos pharma, inc. ceo · lumo NASDAQ · lumos pharma, inc. headquarters · lumos pharma, inc. business segments
About Stock Overview & Key Data
Lumos Pharma, Inc. (LUMO) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Nov 11, 2011. As of the latest trading session, LUMO stock price is $4.34, with a market capitalization of $37.5M. The stock has returned +40.91% over the past 12 months and +0.00% year-to-date.
According to 7 Wall Street analysts, the consensus rating for Lumos Pharma, Inc. stock is Buy, with an average 12-month price target of $16.50. In fiscal year 2023, Lumos Pharma, Inc. reported revenue of $2.1M and net income of -$34.0M. For detailed data — including Lumos Pharma, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Lumos Pharma, Inc. (LUMO) stock price is $4.34. The stock is traded on NASDAQ under the ticker symbol LUMO. The 52-week range is $1.37 – $4.58.